Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.Lancet Oncol. 2010; 11: 627-636
- Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.Lancet Oncol. 2011; 12: 65-82
- Use of angiotensin receptor blockers and the risk of cancer.Circulation. 2011; 123: 1729-1736
- Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension.Am J Cardiol. 2011; 107: 1028-1033
- Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).Eur Heart J. 2009; 30: 1203-1212
- Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?.Lancet. 1998; 352: 179-184
- Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis.Biochem Biophys Res Commun. 2002; 294: 441-447
- Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth.J Clin Invest. 2003; 112: 67-75
- Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis.Cancer Res. 2002; 62: 4176-4179
- Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.J Hypertens. 2011; 29: 623-635
- Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.J Clin Oncol. 2011; 29: 3001-3007
- Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project.Jpn J Clin Oncol. 2011; 41: 139-147
This trial was funded by the Japan Research Promotion Society for Cardiovascular Diseases, Tokyo, Japan, which had no role in the study design, data collection, data analysis, data interpretation, or writing of this report.